Navigation Links
'Cornell Dots' that light up cancer cells go into clinical trials
Date:1/31/2011

ITHACA, N.Y. - "Cornell Dots" brightly glowing nanoparticles may soon be used to light up cancer cells to aid in diagnosing and treating cancer. The U.S. Food and Drug Administration (FDA) has approved the first clinical trial in humans of the new technology. It is the first time the FDA has approved using an inorganic material in the same fashion as a drug in humans.

"The FDA approval finally puts a federal approval stamp on all the assumptions we have been working under for years. This is really, really nice," said Ulrich Wiesner, the Spencer T. Olin Professor of Materials Science and Engineering, who has devoted eight years of research to developing the nanoparticles. "Cancer is a terrible disease, and my family has a long history of it. I, thus, have a particular personal motivation to work in this area."

The trial with five melanoma patients at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City will seek to verify that the dots, also known as C dots, are safe and effective in humans, and to provide data to guide future applications. "This is the first product of its kind. We want to make sure it does what we expect it to do," said Michelle Bradbury, M.D., radiologist at MSKCC and assistant professor of radiology at Weill Cornell Medical College.

C dots are silica spheres less than 8 nanometers in diameter that enclose several dye molecules. (A nanometer is one-billionth of a meter, about the length of three atoms in a row.) The silica shell, essentially glass, is chemically inert and small enough to pass through the body and out in the urine. For clinical applications, the dots are coated with polyethylene glycol so the body will not recognize them as foreign substances.

To make the dots stick to tumor cells, organic molecules that bind to tumor surfaces or even specific locations within tumors can be attached to the shell. When exposed to near-infrared light, the dots fluoresce much brighter than unencapsulated dye to serve as a beacon to identify the target cells. The technology, the researchers say, can show the extent of a tumor's blood vessels, cell death, treatment response and invasive or metastatic spread to lymph nodes and distant organs. The safety and ability to be cleared from the body by the kidneys has been confirmed by studies in mice at MSKCC, reported in the January 2009 issue of the journal Nano Letters (Vol. 9 No. 1).

For the human trials, the dots will be labeled with radioactive iodine, which makes them visible in PET scans to show how many dots are taken up by tumors and where else in the body they go and for how long.

"We do expect it to go to other organs," Bradbury said. "We get numbers, and from that curve derive how much dose each organ gets. And we need to find out how fast it passes through. Are they cleared from the kidney at the same rate as in mice?"

One of many advantages of C dots, Bradbury noted, is that they remain in the body long enough for surgery to be completed. "Surgeons love optical," she said. "They don't need the radioactivity, but [our study] confirms what the optical signal is. As you learn that, eventually you no longer need the radioactivity."

On the other hand, she added, the dots also may serve as a carrier to deliver radioactivity or drugs to tumors. "This is step one to jump-start a process we think will do multiple things with one platform," she said.

First-generation Cornell dots were developed in 2005 by Hooisweng Ow, then a graduate student working with Wiesner. Wiesner, Ow and Kenneth Wang '77 have co-founded the company Hybrid Silica Technologies to commercialize the invention. The dots, Wiesner said, also have possible applications in displays, optical computing, sensors and such microarrays as DNA chips.


'/>"/>

Contact: Blaine Friedlander
bpf2@cornell.edu
607-254-8093
Cornell University
Source:Eurekalert

Related biology news :

1. Gates Foundation continues funding of tuberculosis research at Weill Cornell
2. Cornells regional sun grant energy conference is May 24-26
3. Cornell forges licensing agreement with new New York apple industry group
4. Weill Cornell researchers find that a single gene is responsible for OCD-like behaviors in mice
5. Weill Cornell science briefs: November 2009
6. Battling cancer with engineering: NCI funds new $13 million cancer research center led by Cornell
7. Genetic secrets of date palm unlocked by researchers at Weill Cornell Medical College in Qatar
8. NIST-Cornell team builds worlds first nanofluidic device with complex 3-D surfaces
9. Multicolor quantum dots aid in cancer biopsy diagnosis
10. Connecting the dots: How light receptors get their message across
11. Rice eyes risks of quantum dots
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017 The report "Gesture Recognition and Touchless Sensing ... Geography - Global Forecast to 2022", published by MarketsandMarkets, the market is expected ... 29.63% between 2017 and 2022. Continue Reading ... ... ...
(Date:3/22/2017)... VILNIUS, Lithuania , March 21, 2017 /PRNewswire/ ... identification and object recognition technologies, today announced the ... development kit (SDK), which provides improved facial recognition ... safety cameras on a single computer. The new ... algorithms to improve accuracy, and it utilizes a ...
(Date:3/22/2017)... Vigilant Solutions , a vehicle location ... announced today the appointment of retired FBI special agent ... business development. Mr. Sheridan brings more than ... focus on the aviation transportation sector, to his new ... Sheridan served as the Aviation Liaison Agent Coordinator (ALAC) ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... Orleans, La. (PRWEB) , ... March 23, 2017 ... ... real-time, industrial monitoring solutions, today announced the hire of Dr. Sigmund “Sig” Floyd ... APMT customer applications, strategic partnerships and joint development activities. , “Dr. Floyd’s career ...
(Date:3/22/2017)... COPENHAGEN, Denmark , March 22, 2017 /PRNewswire/ ... that utilizes its innovative TransCon technology to address ... announced financial results for the full year ended ... a significant year for our company as we ... become a leading, integrated rare disease company with ...
(Date:3/22/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... ), a clinical-stage pharmaceutical company focused ... announced today that Dr. Miriam Kidron , ... titled, "Oral Insulin for Diabetes Treatment: Bypassing the ... and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... Florida , March 22, 2017 ... ... various cancer conditions are being pressured as of late due ... for cancer pain management has a dramatic impact on patient,s ... research and development activities for identifying new forms of opioid ...
Breaking Biology Technology: